MA44987A - Formulations de médicaments améliorées - Google Patents
Formulations de médicaments amélioréesInfo
- Publication number
- MA44987A MA44987A MA044987A MA44987A MA44987A MA 44987 A MA44987 A MA 44987A MA 044987 A MA044987 A MA 044987A MA 44987 A MA44987 A MA 44987A MA 44987 A MA44987 A MA 44987A
- Authority
- MA
- Morocco
- Prior art keywords
- drug formulations
- enhanced drug
- enhanced
- formulations
- drug
- Prior art date
Links
- 239000013583 drug formulation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333482P | 2016-05-09 | 2016-05-09 | |
| US201662334576P | 2016-05-11 | 2016-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44987A true MA44987A (fr) | 2019-03-20 |
Family
ID=60267508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044987A MA44987A (fr) | 2016-05-09 | 2017-05-08 | Formulations de médicaments améliorées |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200009060A1 (fr) |
| EP (2) | EP3454847A4 (fr) |
| JP (2) | JP7112333B2 (fr) |
| CN (1) | CN109069460A (fr) |
| AU (1) | AU2017262586B2 (fr) |
| CA (1) | CA3022878C (fr) |
| IL (1) | IL262745B (fr) |
| MA (1) | MA44987A (fr) |
| WO (1) | WO2017196712A1 (fr) |
| ZA (1) | ZA201807446B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019094688A1 (fr) * | 2017-11-10 | 2019-05-16 | Dispersol Technologies, Llc | Formulations améliorées de médicaments |
| US20210128536A1 (en) * | 2019-11-01 | 2021-05-06 | Dispersol Technologies, Llc | Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof |
| EP4119129A4 (fr) * | 2020-03-11 | 2024-01-24 | Sawai Pharmaceutical Co., Ltd. | Granules et preparation mettant en oeuvre ceux-ci |
| WO2022094817A1 (fr) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Formulation pharmaceutique |
| NL2028762B1 (en) * | 2021-07-16 | 2023-01-23 | Seranovo Holding B V | Micelle-generating formulations for enhanced bioavailability |
| CN116173018A (zh) * | 2021-11-26 | 2023-05-30 | 上海宣泰医药科技股份有限公司 | 一种达罗他胺药物组合物及其制备方法和用途 |
| CN114190538B (zh) * | 2021-12-21 | 2023-11-24 | 郑州轻工业大学 | 一种促β′晶型形成的油脂促结晶剂及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA001219B1 (ru) * | 1996-05-20 | 2000-12-25 | Жансен Фармасетика Н.В. | Антигрибковые композиции с улучшенной биологической доступностью |
| US20070218138A1 (en) * | 2006-03-20 | 2007-09-20 | Bittorf Kevin J | Pharmaceutical Compositions |
| CA2990445C (fr) * | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Melange thermocinetique pour des applications pharmaceutiques |
| CN101959504A (zh) * | 2008-02-28 | 2011-01-26 | 比艾尔-坡特拉有限公司 | 用于难溶性药物的药物组合物 |
| US20090269403A1 (en) * | 2008-04-24 | 2009-10-29 | Shaked Ze Ev | Oral contraceptive dosage forms and methods of making such dosage forms |
| EP2291079B1 (fr) * | 2008-05-14 | 2013-04-24 | Merck Sharp & Dohme Corp. | Préparations pour inhibiteurs de la cathepsine k |
| CN102985074B (zh) | 2010-05-10 | 2015-09-02 | 赢创罗姆有限公司 | 包含一种或多种抗逆转录病毒活性成分的药物剂型 |
| WO2012116238A1 (fr) * | 2011-02-23 | 2012-08-30 | Dispersol Technologies, Llc | Formulations pharmaceutiques d'acide acétyl-11-céto-β-boswellique, de diindolylméthane et de curcumine pour applications pharmaceutiques |
| MX2013010306A (es) * | 2011-03-08 | 2013-12-09 | Zalicus Pharmaceuticals Ltd | Formulaciones de dispersion solida y metodos de uso de las mismas. |
| WO2014170026A1 (fr) * | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Ticagrelor amorphe stabilisé |
| WO2015152433A1 (fr) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Dispersion solide amorphe comprenant du paclitaxel, comprimé la comprenant, et son procédé de préparation |
| PL3131667T3 (pl) * | 2014-04-18 | 2022-01-17 | Dispersol Technologies, Llc | Wieloprędkościowy proces i mieszalnik do konserwowania wrażliwych na ciepło porcji termokinetycznie topionych partii |
| WO2015175505A1 (fr) * | 2014-05-15 | 2015-11-19 | Lundbeck Llc | Formulation à libération modifiée de tétrabenazine |
| WO2016073421A1 (fr) * | 2014-11-03 | 2016-05-12 | Dispersol Technologies, Llc | Formulations améliorées de vemurafenib et leurs procédés de fabrication |
| CN104434809B (zh) * | 2014-12-10 | 2018-10-16 | 北京科莱博医药开发有限责任公司 | 一种奥拉帕尼固体分散体制剂及其制备方法 |
| JOP20170127A1 (ar) * | 2016-06-02 | 2017-12-02 | Gilead Pharmasset Llc | صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات |
-
2017
- 2017-05-08 CA CA3022878A patent/CA3022878C/fr active Active
- 2017-05-08 CN CN201780028973.8A patent/CN109069460A/zh active Pending
- 2017-05-08 EP EP17796620.7A patent/EP3454847A4/fr not_active Withdrawn
- 2017-05-08 EP EP25151222.4A patent/EP4552641A3/fr active Pending
- 2017-05-08 WO PCT/US2017/031521 patent/WO2017196712A1/fr not_active Ceased
- 2017-05-08 MA MA044987A patent/MA44987A/fr unknown
- 2017-05-08 IL IL262745A patent/IL262745B/en unknown
- 2017-05-08 JP JP2018558764A patent/JP7112333B2/ja active Active
- 2017-05-08 AU AU2017262586A patent/AU2017262586B2/en active Active
- 2017-05-08 US US16/098,145 patent/US20200009060A1/en active Pending
-
2018
- 2018-11-06 ZA ZA2018/07446A patent/ZA201807446B/en unknown
-
2022
- 2022-05-31 JP JP2022088284A patent/JP7458440B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4552641A2 (fr) | 2025-05-14 |
| CA3022878A1 (fr) | 2017-11-16 |
| AU2017262586A1 (en) | 2018-11-22 |
| CA3022878C (fr) | 2024-04-30 |
| US20200009060A1 (en) | 2020-01-09 |
| JP2019514993A (ja) | 2019-06-06 |
| JP7458440B2 (ja) | 2024-03-29 |
| EP3454847A4 (fr) | 2019-12-18 |
| EP3454847A1 (fr) | 2019-03-20 |
| CN109069460A (zh) | 2018-12-21 |
| ZA201807446B (en) | 2025-05-28 |
| WO2017196712A1 (fr) | 2017-11-16 |
| JP2022116234A (ja) | 2022-08-09 |
| IL262745B (en) | 2022-07-01 |
| IL262745A (en) | 2018-12-31 |
| EP4552641A3 (fr) | 2025-07-30 |
| JP7112333B2 (ja) | 2022-08-03 |
| AU2017262586B2 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268697A (en) | Formulations | |
| DK3688162T3 (da) | Formuleringer | |
| EP3513809A4 (fr) | Composition médicinale | |
| PL4070788T3 (pl) | Formulacje farmaceutyczne | |
| MA50657A (fr) | Formulations de niraparib | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| BR112017027227A2 (pt) | Agente anti-câncer | |
| EP3541385A4 (fr) | Formulations pharmaceutiques | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| EP3424940A4 (fr) | Médicament radiomarqué | |
| EP3603642A4 (fr) | Préparation pharmaceutique | |
| DK3529240T3 (da) | Farmaceutiske forbindelser | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| DK3463345T3 (da) | Farmaceutiske kombinationer | |
| EP3364945C0 (fr) | Formulation solide | |
| MA44987A (fr) | Formulations de médicaments améliorées | |
| EP3437644A4 (fr) | Médicament | |
| EP3527216A4 (fr) | Médicament | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| MA50068A (fr) | Formulations de copanlisib | |
| EP3646866A4 (fr) | Préparation pharmaceutique | |
| IL272167A (en) | Hemopexin formulations | |
| EP3337463A4 (fr) | Formulations pharmaceutiques | |
| EP3334447A4 (fr) | Conjugués médicament-cck2r | |
| HUE069648T2 (hu) | Gyógyszerészeti készítmény |